Allapinin - instructions for use, reviews, analogs and formulations (tablets 25 mg) of a drug for the treatment of tachycardia, extrasystole and other cardiac rhythm disturbances or arrhythmias in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Allapinin. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of experts on the use of Allapinin in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Allapinin in the presence of existing structural analogues.The use for the treatment of tachycardia, arrhythmia and other cardiac arrhythmias or arrhythmias in adults and children, as well as during pregnancy and lactation. Composition of the preparation.

Allapinin - Class 1 antiarrhythmic drug C. Blocks fast sodium channels of membranes of cardiomyocytes. Causes deceleration AV- and intraventricular conduction, shortens the effective and functional refractory periods of the atria, AV-node, bundle of His and Purkinje fibers, does not affect the duration of the interval QT, conductivity AV-node in the anterograde direction, heart rate, blood pressure, cardiac contractility (with initial absence of heart failure).

Do not depress the automatism of the sinus node. Does not cause negative inotropic and hypotensive effect.

VFS has a moderate antispasmodic, koronarorasshiryayuschee, anticholinergic, local anesthetic and sedation. When administered effect develops in 40-60 minutes, reaching a maximum after 80 minutes and lasts 8 hours and more.

Composition

Lappaconitine hydrobromide (VFS) + auxiliaries.

Pharmacokinetics

Bioavailability is 40%.The drug is exposed to the effect of the first passage through the liver. Penetrates through the blood-brain barrier (BBB). It is excreted by the kidneys.

With prolonged use, it is possible to increase the half-life. In chronic renal failure, T1 / 2 increases 2-3 times, with cirrhosis - 3-10 times.

Indications

• supraventricular extrasystole;
• ventricular extrasystole;
• paroxysms of flicker and atrial flutter;
• paroxysmal supraventricular tachycardia (including with WPW syndrome);
• paroxysmal ventricular tachycardia (in the absence of organic lesions of the heart).

Forms of release

Tablets 25 mg.

Instructions for use and dosing regimen

Assign inside 25 mg (1 tablet) every 8 hours, with no therapeutic effect - every 6 hours.

It is possible to increase the single dose to 50 mg (2 tablets) every 6-8 hours. The maximum daily dose is 300 mg (12 tablets).

The duration of treatment and the change in the dosage regimen (increase in the dose) is determined by the doctor.

The drug is taken orally, after eating, squeezed with a small amount of water at room temperature, do not grind the tablets.

Side effect

• dizziness;
• headache;
• a feeling of heaviness in the head;
• ataxia;
• diplopia;
• violations of AV and intraventricular conduction;
• the appearance of sinus tachycardia (with prolonged use);
• arrhythmogenic action;
• changes on the ECG (prolongation of the PQ interval, expansion of the QRS complex);
• hyperemia of the skin;
• allergic reactions.

Contraindications

• sinoatrial blockade;
• AV-blockade of 2 and 3 degrees (without artificial pacemaker);
• cardiogenic shock;
• blockade of the right leg of the bundle of Hisb, combined with the blockade of one of the branches of the left leg;
• severe arterial hypotension (systolic blood pressure less than 90 mm Hg);
• moderate and severe chronic heart failure 3-4 of the functional class according to NYHA classification;
• marked hypertrophy of myocardium of the left ventricle (more than 1.4 cm);
• presence of postinfarction cardiosclerosis;
• severe dysfunction of the liver and / or kidney;
• fructose intolerance, glucose / galactose absorption impairment syndrome, sugarase / isomaltase deficiency (the preparation contains sucrose);
• children and adolescents under 18 years of age (efficacy and safety not established);
• hypersensitivity to the drug.

Application in pregnancy and lactation

Application of the drug Allapinin in pregnancy is not recommended. It is possible to use the drug only for life indications, if the intended benefit for the mother exceeds the potential risk to the fetus or the child.

There is no data on the isolation of lappaconitin hydrobromide in breast milk. The use of the drug is not recommended during breastfeeding. If the use of the drug during lactation is necessary, breastfeeding should be discontinued.

Use in children

Contraindicated in children and adolescents under the age of 18 years (efficacy and safety not established).

special instructions

Before the application of the drug Allapinin, it is necessary to eliminate disturbances in water-electrolyte metabolism, during the period of therapy it is necessary to control the water-electrolyte balance of water.

With caution should be used with AV blockade 1 degree, violation of intraventricular conduction, SSSU, bradycardia, severe violations of peripheral circulation, angle-closure glaucoma, prostatic hypertrophy, impaired conduction along the fibers of Purkinje, blockade of one of the legs of the bundle of Guiss, disturbance of electrolyte metabolism (hypokalemia , hyperkalemia, hypomagnesemia),while taking with other antiarrhythmic drugs.

In patients who underwent acute myocardial infarction, or in patients with heart failure, as well as in patients with an established pacemaker, the threshold of its stimulation may increase.

With the development of headache, dizziness, diplopia should reduce the dose of the drug Allapinin.

When sinus tachycardia appears against the background of long-term use of the drug, beta-blockers in low doses are indicated.

1 tablet contains 74 mg of carbohydrates, which corresponds to 0.01 XE.

Impact on the ability to drive vehicles and manage mechanisms

When using the drug, care should be taken when carrying out potentially hazardous activities requiring special attention and quick reactions (transport management, work with moving mechanisms).

Drug Interactions

With the simultaneous use of microsomal liver enzymes with inducers, the efficacy of lappaconitin hydrobromide decreases, and the risk of toxic effects increases.

Antiarrhythmic drugs of other classes increase the risk of arrhythmogenic action.

Allapinin enhances the effect of nondepolarizing muscle relaxants.

Analogues of the drug Allapinin

Allapinin does not have structural analogs for the active ingredient.

Analogues for the pharmacological group (antiarrhythmics and blockers):

• Adenocorus;
• Amiodarone;
• Amiocordin;
• Asparks;
• Atenolol;
• Betacard;
• Betaxalol;
• Betalk;
• Bidop;
• Bisoprolol;
• Bretilate;
• Dinexan;
• Diphenine;
• Cardiodarone;
• Kinidin Durules;
• Concor;
• Concor Cor;
• Corvitol;
• Cordarone;
• Lappakonitina hydrobromide;
• Lidocaine;
• Lidocaine hydrochloride;
• Metoprolol;
• Multac;
• Nebivolol;
• Non-ticket;
• Neo Giluritmal;
• Nibentan;
• Novocaineamide;
• Opakorden;
• Pamaton;
• Panangin;
• Panangin Forte;
• Prokainami;
• Propanorm;
• Propaphenone;
• Propranolol;
• Profen;
• Refralon;
• Ritalmex;
• Rhythmiodaron;
• Rhythmodan;
• Rhythm monm;
• Sedacorone;
• Sotagexal;
• Sotalol;
• Tenoric;
• Trimecaine;
• Trimecaine injection;
• Egilok;
• Egilok Retard;
• Etatsizin;
• Ethmosin.

Similar medicines:

Other medicines: